

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Gleostine (lomustine)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Gleostine (lomustine)

APPROVAL CRITERIA

Requests for Gleostine (lomustine) may be approved if the following criteria are met:

- I. Individual has a diagnosis of brain tumors, including malignant glioma and brain metastases; **AND**
- II. Individual has already received surgical and/or radiotherapeutic procedures;

OR

- III. Individual has relapsed or refractory Hodgkin's disease;

OR

- IV. Individual has a diagnosis of central nervous system cancer;

AND

- A. Adult intracranial and spinal ependymoma (NCCN 2A); **OR**
- B. Adult low-grade infiltrative supratentorial astrocytoma/oligodendroglioma (NCCN 2A); **OR**
- C. Adult medulloblastoma (NCCN 2A); **OR**
- D. Anaplastic gliomas (NCCN 2A); **OR**
- E. Glioblastoma (NCCN 2A).

Note: Gleostine (lomustine) has a black box warning for bone marrow suppression, most notably thrombocytopenia and leukopenia, which may contribute to bleeding and severe infections. Courses of Gleostine (lomustine) should not be given more frequently than every six weeks at the recommended dosage, and blood counts should be monitored weekly for at least six weeks after a dose. Bone marrow suppression from Gleostine (lomustine) is cumulative

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

and dosage adjustments must be considered on the basis of nadir blood counts from the prior dose.

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed:4/2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.